Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Raw Materials (2023 - 2025)

China SXT Pharmaceuticals has reported Raw Materials over the past 3 years, most recently at $435799.0 for Q1 2025.

  • For Q1 2025, Raw Materials rose 35.88% year-over-year to $435799.0; the TTM value through Mar 2025 reached $435799.0, up 35.88%, while the annual FY2025 figure was $435799.0, 35.88% up from the prior year.
  • Raw Materials for Q1 2025 was $435799.0 at China SXT Pharmaceuticals, up from $320722.0 in the prior quarter.
  • Over five years, Raw Materials peaked at $435799.0 in Q1 2025 and troughed at $243222.0 in Q1 2023.
  • A 3-year average of $333247.7 and a median of $320722.0 in 2024 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: skyrocketed 31.86% in 2024 and later surged 35.88% in 2025.
  • Year by year, Raw Materials stood at $243222.0 in 2023, then skyrocketed by 31.86% to $320722.0 in 2024, then surged by 35.88% to $435799.0 in 2025.
  • Business Quant data shows Raw Materials for SXTC at $435799.0 in Q1 2025, $320722.0 in Q1 2024, and $243222.0 in Q1 2023.